XRAY
Overvalued by 17.6% based on the discounted cash flow analysis.
Market cap | $6.29 Billion |
---|---|
Enterprise Value | $8.08 Billion |
Dividend Yield | $0.5726 (1.89%) |
Earnings per Share | $-0.62 |
Beta | 0.0 |
Outstanding Shares | 207,363,276 |
Avg 30 Day Volume | 4,837,253 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -47.68 |
---|---|
PEG | 8.72 |
Price to Sales | 1.62 |
Price to Book Ratio | 2.05 |
Enterprise Value to Revenue | 2.04 |
Enterprise Value to EBIT | 28.34 |
Enterprise Value to Net Income | -62 |
Total Debt to Enterprise | 0.26 |
Debt to Equity | 0.64 |
No data
No data